Amphastar Pharmaceuticals Inc vs Marathon Digital Holdings Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.85 (market cap $868.62M), while Marathon Digital Holdings Inc trades at $9.63 (market cap $3.74B). The key difference: Marathon Digital Holdings Inc is far larger — about 4.3× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMPH | MARA | |
|---|---|---|
Market Cap | $868.62M | $3.74B |
Sector | Health | Technology |
52-Week High | $30.81 | $22.84 |
52-Week Low | $16.87 | $6.73 |
Enterprise Value | $1.27B | $5.78B |
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $19.87, down 2.19% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.91, beating expectations, but missed in Q4 2025 and Q1 2026. Revenue for 2025 was $719.89M with a net income margin of 10.76%, while valuation ratios like P/E of 12.08 and EV/EBITDA of 6.57 suggest reasonable pricing. Recent news highlights growth from new product launches and ongoing FDA compliance efforts.
The outlook is mixed with growth opportunities from proprietary drugs and biosimilars, but risks include regulatory scrutiny and earnings volatility. Analyst sentiment is cautious with 25% buy ratings, reflecting concerns over execution and market pressures. Investors should weigh solid cash flow generation against competitive and regulatory headwinds for balanced exposure.
Marathon Digital Holdings (MARA) trades at $9.95, up 4.08% today but remains under pressure with a bearish technical signal. The company reported a Q2 2026 net loss of $1.60 per share, missing estimates, as revenue fell to $804 million with a net income margin of -429.71%. Despite negative cash flow from operations, MARA is pivoting toward AI digital infrastructure, appointing new directors to support growth. Analyst consensus is mixed with a $16.08 price target but high volatility persists.
MARA's outlook is challenged by persistent losses and high execution risk in its strategic shift, though its low P/E of 3.37 suggests deep value if the AI pivot succeeds. Key risks include Bitcoin price sensitivity, competitive pressures, and cash burn. Investors should weigh the 50% buy rating against fundamental weaknesses before considering a position.
Trailing returns across standard periods
Latest headlines on both assets
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →